IP Library Granted Patent US 8,980,277
Granted Patent B2
US 8,980,277 · App. 10/488,786 · Granted Mar 17, 2015

Hybrid and tandem expression of neisserial proteins

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,980,277
App. No.
10/488,786
Granted
Mar 17, 2015
Kind
B2
Abstract

Two or more Neisserial proteins are joined such that they are translated as a single polypeptide chain. Hybrid proteins are represented by the formula NH 2 -A-[-X-L-] n -B—COOH where X is an amino acid sequence, L is an optional linker amino acid sequence, A is an optional N-terminal amino acid sequence, B is an optional C-terminal amino acid sequence, and n is an integer greater than 1. Proteins where each of the n -X- moieties shares sequence identity to each other -X- moiety, the protein is a ‘tandem protein’.

Claims (11)

1. The hybrid protein comprising formula:

NH 2 -A-[-X-L-] n -B—COOH

wherein L is an optional linker amino acid sequence, A is an optional N-terminal amino acid sequence, B is an optional C-terminal amino acid sequence, and n is an integer greater than 1 and an X 1 portion of the NH 2 -A-[-X-L-] n -B—COOH formula comprises an amino acid sequence having at least 90% identity to SEQ ID NO: 2206 and an X 2 portion of the NH 2 -A-[-X-L-] n -B—COOH formula comprises an amino acid sequence having at least 90% identity to SEQ ID NO: 2207.

2. The hybrid protein of claim 1 wherein n=2.

3. The hybrid protein of claim 1 , wherein L has 20 or fewer amino acids.

4. The hybrid protein of claim 1 , wherein L is a poly-glycine linker.

5. The hybrid protein of claim 4 , wherein the poly-glycine linker is GSGGGG (SEQ ID NO: 27).

6. The hybrid protein of claim 1 , wherein A has 40 or fewer amino acids.

7. The hybrid protein of claim 1 , wherein B has 40 or fewer amino acids.

8. A composition comprising the hybrid protein of claim 1 and a pharmaceutically acceptable carrier.

9. A method of inducing an immune response in a subject, comprising administering to the subject an effective amount of the composition of claim 8 .

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 20, 2016
From: NOVARTIS VACCINES AND DIAGNOSTICS SRL
To: GLAXOSMITHKLINE BIOLOGICALS SA
Reel/Frame 040077/0722 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 19, 2005
From: MARIAGRAZIA PIZZA
To: CHIRON S.R.L.
Reel/Frame 016106/0536 →